Le Lézard
Classified in: Health
Subjects: AWD, AVO

Texas Fertility Center Physicians Only Reproductive Endocrinologists in Austin to Be Named Castle Connolly Top Doctors


AUSTIN, Texas, Jan. 16, 2018 /PRNewswire-PRWeb/ -- All five reproductive endocrinologists at Texas Fertility Center (TFC) have once again been selected as Top Doctors by Castle Connolly Medical Ltd., a healthcare research and information company that helps guide consumers to the top doctors and hospitals in the United States. The TFC physicians are the only reproductive endocrinologists in Austin to receive the designation of Castle Connolly Top Doctors.

To determine the Castle Connolly Top Doctors, a physician-led team of researchers identifies the candidates, who were all nominated by other physicians in their field at the national and regional levels. The selection process is designed to identify the doctors who other doctors believe are the best in their field.

The TFC reproductive endocrinologists?and Castle Connolly Top Doctors?include Thomas Vaughn MD, Kaylen Silverberg MD, Lisa Hansard MD, Natalie Burger MD and Anthony Propst MD, who have more than 100 years of combined medical experience between them. Summer James, MD, from TFC's San Antonio office, was also recognized as a Top Doctor in San Antonio. In addition to being board-certified OB/GYNs, all TFC physicians are also board certified in reproductive endocrinology and infertility. This means that, in addition to the training received by all OB/GYNs, each TFC physician received two to three additional years of specialized training in infertility, recurrent pregnancy loss, in vitro fertilization and complicated reproductive surgery.

According to Dr. Silverberg, "It is a true honor to have all of our physicians be recognized as Castle Connolly Top Doctors. The Texas Fertility Center team is committed to providing men and women with the best fertility care and patient experience available to help patients become parents. Each of our fertility specialists also believes in the importance of advancing the field of reproductive medicine, so our physicians conduct fertility research which we present and publish in order to help other fertility specialists improve pregnancy rates for their patients."

The TFC difference

With a commitment to reducing the cost of a live birth for all, the Central and South Texas fertility center is renowned for its leading-edge care. Each TFC physician combines the latest assisted reproductive technologies with compassionate care to develop effective individualized treatment plans. Highly trained and experienced andrologists, embryologists and geneticists support these efforts in the IVF and andrology laboratories.

As part of their commitment to help make parenthood possible for all patients, the physicians at TFC are actively involved in groundbreaking fertility research, presenting seven papers at the 2017 American Society for Reproductive Medicine (ASRM) meeting. The physicians are also able to extend their reach and help more men and women through a partnership with Ovation Fertilitytm, an industry leader in reproductive medicine and embryonic genetic testing.

Using their experience and influence, the team at TFC also lobbies at the national and local levels for increased access to affordable fertility care in the United States. These efforts include advocating for greater insurance coverage for fertility treatments and increased awareness of infertility as a treatable disease.

About Texas Fertility Center

Texas Fertility Center (TFC), one of the nation's leading full-service infertility practices, provides advanced infertility and reproductive endocrinology services to patients throughout Texas, the southwestern United States and the Americas. Since 1980, TFC has been recognized nationally for outstanding pregnancy rates, leading-edge laboratory procedures and innovative research programs. For more information, please visit http://www.txfertility.com.

 

SOURCE Texas Fertility Center


These press releases may also interest you

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

at 17:30
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association...

at 17:19
Long-time Madison podiatrist Colin Graney, DPM, has announced both the closing of his practice and that the Board Certified and Fellowship Trained physicians at Orthopedic & Spine Centers of Wisconsin will provide continuing care for his patients....

at 17:03
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary...

at 16:42
Accelerate Diagnostics, Inc. today announced financial preliminary results for the first quarter ended March 31, 2024. "During the...

at 16:40
Johnson & Johnson will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12th, at the Loews Miami Beach Hotel, Miami Beach, Florida. Jennifer Taubert, Executive Vice President, Worldwide Chairman,...



News published on and distributed by: